Related Experiment Video

Updated: May 13, 2026

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

BRAF inhibitor activity in V600R metastatic melanoma--response

Oliver Klein, Arthur Clements, Alexander M Menzies

    European Journal of Cancer (Oxford, England : 1990)
    |March 16, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    A Melanoma Patient-Derived Xenograft Model
    07:07

    A Melanoma Patient-Derived Xenograft Model

    Published on: May 20, 2019

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
    07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    Related Experiment Videos

    Last Updated: May 13, 2026

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
    08:18

    Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

    Published on: September 8, 2021

    A Melanoma Patient-Derived Xenograft Model
    07:07

    A Melanoma Patient-Derived Xenograft Model

    Published on: May 20, 2019

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
    07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Analytical Performance of the Avida Duo Assay for Simultaneous Mutation and Methylation Profiling in Circulating Cell-Free DNA.

    Cancers·2026

    Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

    European journal of cancer (Oxford, England : 1990)·2026

    Distinctive features of the tumor and immune microenvironment in glioblastoma.

    NPJ precision oncology·2026

    Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study.

    JCO precision oncology·2026

    Vulval Lichen Sclerosus Associated With Immune Checkpoint Inhibitor Therapy: A Case Series of 11 Patients.

    The Australasian journal of dermatology·2026

    Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.

    Nature medicine·2026

    Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial.

    European journal of cancer (Oxford, England : 1990)·2026

    Older adults with resectable gastric cancer undergoing perioperative chemotherapy or preoperative chemoradiotherapy plus perioperative chemotherapy: A secondary analysis of the AGITG TOPGEAR phase III trial.

    European journal of cancer (Oxford, England : 1990)·2026

    Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe.

    European journal of cancer (Oxford, England : 1990)·2026

    Hypomethylating agents with venetoclax for newly diagnosed acute myeloid leukemia in patients 65 and older in The Netherlands - A nationwide study of drug usage and treatment outcomes.

    European journal of cancer (Oxford, England : 1990)·2026

    Spectral cytometry-based immune profiling coupled with machine learning identifies circulating Th1-like cells as a blood biomarker for advanced colorectal adenomas.

    European journal of cancer (Oxford, England : 1990)·2026

    Systemic therapies for gastroenteropancreatic neuroendocrine carcinomas: Current paradigm and future avenues.

    European journal of cancer (Oxford, England : 1990)·2026

    Non-antibiotic treatments for the management of recurrent urinary tract infection in the multidrug resistance era: A narrative review.

    Investigative and clinical urology·2026

    Genetic susceptibility to aminoglycoside cochleotoxicity in South African multidrug-resistant and rifampicin-resistant tuberculosis patients.

    The South African journal of communication disorders = Die Suid-Afrikaanse tydskrif vir Kommunikasieafwykings·2026

    Metagenome-scale modeling to assess microbiome metabolic complementarity for precision microbiota transplantation therapies.

    Gut microbes·2026

    Emergence of SCCmec variants causing false-negative MRSA results by Xpert SA Nasal Complete: a need for culture back-up?

    ASM case reports·2026

    Stenotrophomonas maltophilia in the Antimicrobial Resistance Era: Species-Complex Taxonomy, Pathogenesis, Evolving Therapeutic Priorities, and Genomic Surveillance.

    Infection and drug resistance·2026

    Bronchoalveolar Lavage Fluid Lipoarabinomannan as a Rapid Rule-Out Tool for Smear-Negative Pulmonary Tuberculosis in a Nonhuman Immunodeficiency Virus-Predominant, High-Burden Setting: A Prospective Study.

    Open forum infectious diseases·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us